New biologic-response modifiers in ocular inflammatory disease: beyond anti-TNF treatment

References

• Durrani K, Zakka FR, Ahmed M, Memon M, Siddique SS, Foster CS. Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease. Surv. Ophthalmol. 56(6), 474–510 (2011).
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Thurau S, Hennig M, Grajewski RS, Wildner G. Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease. Graefes Arch. Clin. Exp. Ophthalmol. 248(11), 1531–1551 (2010).
   PubMed Web of Science ®Google Scholar
• Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J. Immunol. 125(4), 1678–1685 (1980).
   PubMed Web of Science ®Google Scholar
• Bubien JK, Zhou LJ, Bell PD, Frizzell RA, Tedder TF. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J. Cell Biol. 121(5), 1121–1132 (1993).
   PubMed Web of Science ®Google Scholar
• Golay JT, Clark EA, Beverley PC. The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J. Immunol. 135(6), 3795–3801 (1985).
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW et al.; REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, Phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54(9), 2793–2806 (2006).
   PubMed Web of Science ®Google Scholar
• Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350(25), 2572–2581 (2004).
   PubMed Web of Science ®Google Scholar
• Emery P, Fleischmann R, Filipowicz-Sosnowska A et al.; DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a Phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 54(5), 1390–1400 (2006).
   PubMed Web of Science ®Google Scholar
• Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 52(1), 262–268 (2005).
   PubMed Web of Science ®Google Scholar
• Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83(2), 435–445 (1994).
   PubMed Web of Science ®Google Scholar
• Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22(47), 7359–7368 (2003).
   PubMed Web of Science ®Google Scholar
• Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 54(2), 613–620 (2006).
   PubMed Web of Science ®Google Scholar
• Tappeiner C, Heinz C, Specker C, Heiligenhaus A. Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Res. 39(3), 184–186 (2007).
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Pontikaki I, Modorati G, Bandello F, Meroni PL, Gerloni V. Rituximab for uveitis. Ophthalmology 118(1), 223–224 (2011).
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Miserocchi E, Heinz C, Gerloni V, Kotaniemi K. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford) 50(8), 1390–1394 (2011).
   PubMed Web of Science ®Google Scholar
• Parikh JG, Tawansy KA, Rao NA. Immunohistochemical study of chronic nongranulomatous anterior uveitis in juvenile idiopathic arthritis. Ophthalmology 115(10), 1833–1836 (2008).
   PubMed Web of Science ®Google Scholar
• Sadreddini S, Noshad H, Molaeefard M, Noshad R. Treatment of retinal vasculitis in Behçet’s disease with rituximab. Mod. Rheumatol. 18(3), 306–308 (2008).
   PubMed Web of Science ®Google Scholar
• Davatchi F, Shams H, Rezaipoor M et al. Rituximab in intractable ocular lesions of Behçet’s disease; randomized single-blind control study (pilot study). Int. J. Rheum. Dis. 13(3), 246–252 (2010).
   PubMed Web of Science ®Google Scholar
• Dolz-Marco R, Gallego-Pinazo R, Díaz-Llopis M. Rituximab in refractory Vogt-Koyanagi-Harada disease. J. Ophthalmic Inflamm. Infect. 1(4), 177–180 (2011).
   PubMedGoogle Scholar
• Hansen A, Odendahl M, Reiter K et al. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren’s syndrome. Arthritis Rheum. 46(8), 2160–2171 (2002).
   PubMed Web of Science ®Google Scholar
• Meijer JM, Meiners PM, Vissink A et al. Effectiveness of rituximab treatment in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 62(4), 960–968 (2010).
   PubMed Web of Science ®Google Scholar
• Dass S, Bowman SJ, Vital EM et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann. Rheum. Dis. 67(11), 1541–1544 (2008).
   PubMed Web of Science ®Google Scholar
• Ahmadi-Simab K, Lamprecht P, Nölle B, Ai M, Gross WL. Successful treatment of refractory anterior scleritis in primary Sjogren’s syndrome with rituximab. Ann. Rheum. Dis. 64(7), 1087–1088 (2005).
   PubMed Web of Science ®Google Scholar
• Zapata LF, Agudelo LM, Paulo JD, Pineda R. Sjögren keratoconjunctivitis sicca treated with rituximab. Cornea 26(7), 886–887 (2007).
   Google Scholar
• Chauhan S, Kamal A, Thompson RN, Estrach C, Moots RJ. Rituximab for treatment of scleritis associated with rheumatoid arthritis. Br. J. Ophthalmol. 93(7), 984–985 (2009).
   PubMed Web of Science ®Google Scholar
• Iaccheri B, Androudi S, Bocci EB, Gerli R, Cagini C, Fiore T. Rituximab treatment for persistent scleritis associated with rheumatoid arthritis. Ocul. Immunol. Inflamm. 18(3), 223–225 (2010).
   PubMed Web of Science ®Google Scholar
• Freidlin J, Wong IG, Acharya N. Rituximab treatment for peripheral ulcerative keratitis associated with Wegener’s granulomatosis. Br. J. Ophthalmol. 91(10), 1414 (2007).
   PubMed Web of Science ®Google Scholar
• Huerva V, Sanchez MC, Traveset A, Jurjo C, Ruiz A. Rituximab for peripheral ulcerative keratitis with wegener granulomatosis. Cornea 29(6), 708–710 (2010).
   PubMed Web of Science ®Google Scholar
• Cheung CM, Murray PI, Savage CO. Successful treatment of Wegener’s granulomatosis associated scleritis with rituximab. Br. J. Ophthalmol. 89(11), 1542 (2005).
   PubMed Web of Science ®Google Scholar
• Onal S, Kazokoglu H, Koc A, Yavuz S. Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener’s granulomatosis. Ocul. Immunol. Inflamm. 16(5), 230–232 (2008).
   PubMed Web of Science ®Google Scholar
• Aries PM, Hellmich B, Voswinkel J et al. Lack of efficacy of rituximab in Wegener’s granulomatosis with refractory granulomatous manifestations. Ann. Rheum. Dis. 65(7), 853–858 (2006).
   PubMed Web of Science ®Google Scholar
• Brihaye B, Aouba A, Pagnoux C, Cohen P, Lacassin F, Guillevin L. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener’s granulomatosis: a study on 8 patients. Clin. Exp. Rheumatol. 25(1 Suppl. 44), S23–S27 (2007).
   Web of Science ®Google Scholar
• Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener’s granulomatosis: report of a prospective, open-label pilot trial. Am. J. Respir. Crit. Care Med. 173(2), 180–187 (2006).
   PubMed Web of Science ®Google Scholar
• Omdal R, Wildhagen K, Hansen T, Gunnarsson R, Kristoffersen G. Anti-CD20 therapy of treatment-resistant Wegener’s granulomatosis: favourable but temporary response. Scand. J. Rheumatol. 34(3), 229–232 (2005).
   PubMed Web of Science ®Google Scholar
• Tamura N, Matsudaira R, Hirashima M et al. Two cases of refractory Wegener’s granulomatosis successfully treated with rituximab. Intern. Med. 46(7), 409–414 (2007).
   PubMed Web of Science ®Google Scholar
• Taylor SR, Salama AD, Joshi L, Pusey CD, Lightman SL. Rituximab is effective in the treatment of refractory ophthalmic Wegener’s granulomatosis. Arthritis Rheum. 60(5), 1540–1547 (2009).
   PubMed Web of Science ®Google Scholar
• Joshi L, Lightman SL, Salama AD, Shirodkar AL, Pusey CD, Taylor SR. Rituximab in refractory ophthalmic Wegener’s granulomatosis: PR3 titers may predict relapse, but repeat treatment can be effective. Ophthalmology 118(12), 2498–2503 (2011).
   Google Scholar
• de Menthon M, Cohen P, Pagnoux C et al. Infliximab or rituximab for refractory Wegener’s granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clin. Exp. Rheumatol. 29(1 Suppl. 64), S63–S71 (2011).
   Google Scholar
• Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology 117(5), 861–869 (2010).
   PubMed Web of Science ®Google Scholar
• Khanna D, Chong KK, Afifiyan NF et al. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology 117(1), 133–139.e2 (2010).
   PubMed Web of Science ®Google Scholar
• Pe’er J, Hochberg FH, Foster CS. Clinical review: treatment of vitreoretinal lymphoma. Ocul. Immunol. Inflamm. 17(5), 299–306 (2009).
   PubMed Web of Science ®Google Scholar
• Gea-Banacloche JC. Rituximab-associated infections. Semin. Hematol. 47(2), 187–198 (2010).
   PubMed Web of Science ®Google Scholar
• Stoll ML, Gotte AC. Biological therapies for the treatment of juvenile idiopathic arthritis: lessons from the adult and pediatric experiences. Biologics 2(2), 229–252 (2008).
   PubMedGoogle Scholar
• Stilling-Vinther MK, Pedersen BS. Fatal Pneumocystis jirovecii pneumonia following immunosuppressive therapy with rituximab and prednisolone for posterior scleritis. Acta Ophthalmol. doi:10.1111/j.1755-3768.2011.02127.x (2011) (Epub ahead of print).
   Google Scholar
• McDyer JF, Li Z, John S, Yu X, Wu CY, Ragheb JA. IL-2 receptor blockade inhibits late, but not early, IFN-γ and CD40 ligand expression in human T cells: disruption of both IL-12-dependent and -independent pathways of IFN-γ production. J. Immunol. 169(5), 2736–2746 (2002).
   PubMedGoogle Scholar
• Li Z, Lim WK, Mahesh SP, Liu B, Nussenblatt RB. Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis. J. Immunol. 174(9), 5187–5191 (2005).
   PubMed Web of Science ®Google Scholar
• Sen HN, Levy-Clarke G, Faia LJ et al. High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis. Am. J. Ophthalmol. 148(5), 696–703.e1 (2009).
   PubMed Web of Science ®Google Scholar
• Caspi RR, Roberge FG, McAllister CG et al. T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat. J. Immunol. 136(3), 928–933 (1986).
   PubMed Web of Science ®Google Scholar
• Feron EJ, Calder VL, Lightman SL. Distribution of IL-2R and CD45Ro expression on CD4+ and CD8+ T-lymphocytes in the peripheral blood of patients with posterior uveitis. Curr. Eye Res. 11(Suppl.), 167–172 (1992).
   PubMed Web of Science ®Google Scholar
• Okada AA, Sakai J, Usui M, Mizuguchi J. Intraocular cytokine quantification of experimental autoimmune uveoretinitis in rats. Ocul. Immunol. Inflamm. 6(2), 111–120 (1998).
   PubMed Web of Science ®Google Scholar
• Guex-Crosier Y, Raber J, Chan CC et al. Humanized antibodies against the α-chain of the IL-2 receptor and against the β-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. J. Immunol. 158(1), 452–458 (1997).
   PubMed Web of Science ®Google Scholar
• Vincenti F, Kirkman R, Light S et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N. Engl. J. Med. 338(3), 161–165 (1998).
   PubMed Web of Science ®Google Scholar
• Wynn D, Kaufman M, Montalban X et al.; CHOICE investigators. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a Phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon β. Lancet Neurol. 9(4), 381–390 (2010).
   PubMed Web of Science ®Google Scholar
• Lee SJ, Zahrieh D, Agura E et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 104(5), 1559–1564 (2004).
   PubMed Web of Science ®Google Scholar
• Krueger JG, Walters IB, Miyazawa M et al. Successful in vivo blockade of CD25 (high-affinity interleukin-2-receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J. Am. Acad. Dermatol. 43(3), 448–458 (2000).
   PubMed Web of Science ®Google Scholar
• Waldmann TA. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene 26(25), 3699–3703 (2007).
   PubMed Web of Science ®Google Scholar
• Beniaminovitz A, Itescu S, Lietz K et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N. Engl. J. Med. 342(9), 613–619 (2000).
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Fortin E, Schiffman R et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a Phase I/II clinical trial. Proc. Natl Acad. Sci. USA. 96(13), 7462–7466 (1999).
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Thompson DJ, Li Z et al. Humanized anti-interleukin-2 (IL-2) receptor α therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J. Autoimmun. 21(3), 283–293 (2003).
   PubMed Web of Science ®Google Scholar
• Papaliodis GN, Chu D, Foster CS. Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 110(4), 786–789 (2003).
   PubMed Web of Science ®Google Scholar
• Wroblewski K, Sen HN, Yeh S et al. Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease. Can. J. Ophthalmol. 46(4), 322–328 (2011).
   PubMed Web of Science ®Google Scholar
• Sobrin L, Huang JJ, Christen W, Kafkala C, Choopong P, Foster CS. Daclizumab for treatment of birdshot chorioretinopathy. Arch. Ophthalmol. 126(2), 186–191 (2008).
   PubMed Web of Science ®Google Scholar
• Yeh S, Wroblewski K, Buggage R et al. High-dose humanized anti-IL-2 receptor α antibody (daclizumab) for the treatment of active, noninfectious uveitis. J. Autoimmun. 31(2), 91–97 (2008).
   PubMed Web of Science ®Google Scholar
• Bhat P, Castañeda-Cervantes RA, Doctor PP, Foster CS. Intravenous daclizumab for recalcitrant ocular inflammatory disease. Graefes Arch. Clin. Exp. Ophthalmol. 247(5), 687–692 (2009).
   PubMed Web of Science ®Google Scholar
• Anzaar F, Gallagher MJ, Bhat P, Arif M, Farooqui S, Foster CS. Use of systemic T-lymphocyte signal transduction inhibitors in the treatment of atopic keratoconjunctivitis. Cornea 27(8), 884–888 (2008).
   PubMed Web of Science ®Google Scholar
• Fiorelli VM, Dantas PE, Jackson AT, Nishiwaki-Dantas MC. Systemic monoclonal antibody therapy (daclizumab) in the treatment of cicatrizing conjunctivitis in stevens-johnson syndrome, refractory to conventional therapy. Curr. Eye Res. 35(12), 1057–1062 (2010).
   Web of Science ®Google Scholar
• Buggage RR, Levy-Clarke G, Sen HN et al. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet’s disease. Ocul. Immunol. Inflamm. 15(2), 63–70 (2007).
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Peterson JS, Foster CS et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 112(5), 764–770 (2005).
   PubMed Web of Science ®Google Scholar
• Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC. Interleukin-2-receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 77(2), 166–176 (2004).
   PubMed Web of Science ®Google Scholar
• Hershberger RE, Starling RC, Eisen HJ et al. Daclizumab to prevent rejection after cardiac transplantation. N. Engl. J. Med. 352(26), 2705–2713 (2005).
   PubMed Web of Science ®Google Scholar
• Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J. Am. Soc. Nephrol. 13(2), 559–575 (2002).
   PubMed Web of Science ®Google Scholar
• Shao H, Woon MD, Nakamura S et al. Requirement of B7-mediated costimulation in the induction of experimental autoimmune anterior uveitis. Invest. Ophthalmol. Vis. Sci. 42(9), 2016–2021 (2001).
   PubMed Web of Science ®Google Scholar
• Silver PB, Hathcock KS, Chan CC, Wiggert B, Caspi RR. Blockade of costimulation through B7/CD28 inhibits experimental autoimmune uveoretinitis, but does not induce long-term tolerance. J. Immunol. 165(9), 5041–5047 (2000).
   PubMed Web of Science ®Google Scholar
• Verwaerde C, Naud MC, Delanoye A et al. Ocular transfer of retinal glial cells transduced ex vivo with adenovirus expressing viral IL-10 or CTLA4-Ig inhibits experimental autoimmune uveoretinitis. Gene Ther. 10(23), 1970–1981 (2003).
   PubMed Web of Science ®Google Scholar
• Genovese MC, Becker JC, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N. Engl. J. Med. 353(11), 1114–1123 (2005).
   PubMed Web of Science ®Google Scholar
• Schiff M, Keiserman M, Codding C et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a Phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann. Rheum. Dis. 67(8), 1096–1103 (2008).
   PubMed Web of Science ®Google Scholar
• Schiff M, Keiserman M, Codding C et al. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study. Ann. Rheum. Dis. 70(11), 2003–2007 (2011).
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell DJ, Quartier P et al.; Paediatric Rheumatology International Trials Organization and the Pediatric Rheumatology Collaborative Study Group. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 62(6), 1792–1802 (2010).
   PubMed Web of Science ®Google Scholar
• Angeles-Han S, Flynn T, Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis- a case report. J. Rheumatol. 35(9), 1897–1898 (2008).
   PubMed Web of Science ®Google Scholar
• Zulian F, Balzarin M, Falcini F et al. Abatacept for severe anti-tumor necrosis factor-α refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res. (Hoboken). 62(6), 821–825 (2010).
   PubMed Web of Science ®Google Scholar
• Elhai M, Deslandre CJ, Kahan A. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article by Zulian et al. Arthritis Care Res. (Hoboken) 63(2), 307–8; author reply 308 (2011).
   PubMed Web of Science ®Google Scholar
• Kenawy N, Cleary G, Mewar D, Beare N, Chandna A, Pearce I. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch. Clin. Exp. Ophthalmol. 249(2), 297–300 (2011).
   PubMed Web of Science ®Google Scholar
• Weinblatt M, Schiff M, Goldman A et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann. Rheum. Dis. 66(2), 228–234 (2007).
   PubMed Web of Science ®Google Scholar
• Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann. Rheum. Dis. 68(1), 25–32 (2009).
   PubMed Web of Science ®Google Scholar
• Simon TA, Smitten AL, Franklin J et al. Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann. Rheum. Dis. 68(12), 1819–1826 (2009).
   PubMed Web of Science ®Google Scholar
• Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. Clin. Rheumatol. 27(1), 67–76 (2008).
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N. Engl. J. Med. 328(2), 106–113 (1993).
   PubMed Web of Science ®Google Scholar
• Schiff MH. Role of interleukin-1 and interleukin-1 receptor antagonist in the mediation of rheumatoid arthritis. Ann. Rheum. Dis. 59(Suppl. 1), i103–i108 (2000).
   PubMed Web of Science ®Google Scholar
• Moltó A, Olivé A. Anti-IL-1 molecules: new comers and new indications. Joint. Bone. Spine 77(2), 102–107 (2010).
   PubMed Web of Science ®Google Scholar
• Fleischmann RM. Addressing the safety of anakinra in patients with rheumatoid arthritis. Rheumatology (Oxford) 42(Suppl. 2), ii29–ii35 (2003).
   Google Scholar
• Rosenbaum JT, Boney RS. Activity of an interleukin 1 receptor antagonist in rabbit models of uveitis. Arch. Ophthalmol. 110(4), 547–549 (1992).
   PubMedGoogle Scholar
• de Vos AF, Klaren VN, Kijlstra A. Expression of multiple cytokines and IL-1RA in the uvea and retina during endotoxin-induced uveitis in the rat. Invest. Ophthalmol. Vis. Sci. 35(11), 3873–3883 (1994).
   Google Scholar
• Dana MR, Dai R, Zhu S, Yamada J, Streilein JW. Interleukin-1 receptor antagonist suppresses Langerhans cell activity and promotes ocular immune privilege. Invest. Ophthalmol. Vis. Sci. 39(1), 70–77 (1998).
   PubMed Web of Science ®Google Scholar
• Benezra D, Maftzir G, Barak V. Blood serum interleukin-1 receptor antagonist in pars planitis and ocular Behçet disease. Am. J. Ophthalmol. 123(5), 593–598 (1997).
   PubMedGoogle Scholar
• Planck SR, Woods A, Clowers JS, Nicklin MJ, Rosenbaum JT, Rosenzweig HL. Impact of IL-1 signalling on experimental uveitis and arthritis. Ann. Rheum. Dis. 71(5), 753–760 (2012).
   PubMed Web of Science ®Google Scholar
• Lim WK, Fujimoto C, Ursea R et al. Suppression of immune-mediated ocular inflammation in mice by interleukin-1 receptor antagonist administration. Arch. Ophthalmol. 123(7), 957–963 (2005).
   PubMed Web of Science ®Google Scholar
• Trittibach P, Barker SE, Broderick CA et al. Lentiviral-vector-mediated expression of murine IL-1 receptor antagonist or IL-10 reduces the severity of endotoxin-induced uveitis. Gene Ther. 15(22), 1478–1488 (2008).
   PubMed Web of Science ®Google Scholar
• Tsai ML, Horng CT, Chen SL, Xiao X, Wang CH, Tsao YP. Suppression of experimental uveitis by a recombinant adeno-associated virus vector encoding interleukin-1 receptor antagonist. Mol. Vis. 15, 1542–1552 (2009).
   PubMed Web of Science ®Google Scholar
• Moore JE, McMullen TC, Campbell IL et al. The inflammatory milieu associated with conjunctivalized cornea and its alteration with IL-1 RA gene therapy. Invest. Ophthalmol. Vis. Sci. 43(9), 2905–2915 (2002).
   PubMed Web of Science ®Google Scholar
• Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest. Ophthalmol. Vis. Sci. 42(10), 2283–2292 (2001).
   PubMed Web of Science ®Google Scholar
• Teoh SC, Sharma S, Hogan A, Lee R, Ramanan AV, Dick AD. Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. Br. J. Ophthalmol. 91(2), 263–264 (2007).
   PubMed Web of Science ®Google Scholar
• Terrada C, Neven B, Boddaert N et al. Ocular modifications in a young girl with cryopyrin-associated periodic syndromes responding to interleukin-1 receptor antagonist anakinra. J. Ophthalmic Inflamm. Infect. 1(3), 133–136 (2011).
   PubMedGoogle Scholar
• Bresnihan B, Alvaro-Gracia JM, Cobby M et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41(12), 2196–2204 (1998).
   PubMed Web of Science ®Google Scholar
• Fleischmann RM, Tesser J, Schiff MH et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann. Rheum. Dis. 65(8), 1006–1012 (2006).
   PubMed Web of Science ®Google Scholar
• Meyer O. Interferons and autoimmune disorders. Joint. Bone. Spine 76(5), 464–473 (2009).
   PubMed Web of Science ®Google Scholar
• Liu X, Yang P, Wang C, Li F, Kijlstra A. IFN-α blocks IL-17 production by peripheral blood mononuclear cells in Behçet’s disease. Rheumatology (Oxford). 50(2), 293–298 (2011).
   PubMed Web of Science ®Google Scholar
• Plskova J, Greiner K, Muckersie E, Duncan L, Forrester JV. Interferon-α: a key factor in autoimmune disease? Invest. Ophthalmol. Vis. Sci. 47(9), 3946–3950 (2006).
   PubMed Web of Science ®Google Scholar
• Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-α in autoimmune diseases. Proc. Natl Acad. Sci. USA. 102(9), 3372–3377 (2005).
   PubMed Web of Science ®Google Scholar
• Kötter I, Günaydin I, Zierhut M, Stübiger N. The use of interferon α in Behçet disease: review of the literature. Semin. Arthritis Rheum. 33(5), 320–335 (2004).
   PubMed Web of Science ®Google Scholar
• Kötter I, Zierhut M, Eckstein AK et al. Human recombinant interferon-α-2a for the treatment of Behçet’s disease with sight threatening posterior or panuveitis. Br. J. Ophthalmol. 87(4), 423–431 (2003).
   PubMed Web of Science ®Google Scholar
• Kötter I, Eckstein AK, Stübiger N, Zierhut M. Treatment of ocular symptoms of Behçet’s disease with interferon-α 2a: a pilot study. Br. J. Ophthalmol. 82(5), 488–494 (1998).
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Güney-Tefekli E, Urgancioglu M. Results of interferon-α therapy in patients with Behçet uveitis. Graefes Arch. Clin. Exp. Ophthalmol. 244(12), 1692–1695 (2006).
   PubMed Web of Science ®Google Scholar
• Wechsler B, Bodaghi B, Huong DL et al. Efficacy of interferon-α-2a in severe and refractory uveitis associated with Behçet’s disease. Ocul. Immunol. Inflamm. 8(4), 293–301 (2000).
   PubMed Web of Science ®Google Scholar
• Gueudry J, Wechsler B, Terrada C et al. Long-term efficacy and safety of low-dose interferon α-2a therapy in severe uveitis associated with Behçet disease. Am. J. Ophthalmol. 146(6), 837–44.e1 (2008).
   PubMed Web of Science ®Google Scholar
• Deuter CM, Zierhut M, Möhle A, Vonthein R, Stöbiger N, Kötter I. Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet’s disease. Arthritis Rheum. 62(9), 2796–2805 (2010).
   PubMed Web of Science ®Google Scholar
• Plskova J, Greiner K, Forrester JV. Interferon-α as an effective treatment for noninfectious posterior uveitis and panuveitis. Am. J. Ophthalmol. 144(1), 55–61 (2007).
   PubMed Web of Science ®Google Scholar
• Bodaghi B, Gendron G, Wechsler B et al. Efficacy of interferon-α in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br. J. Ophthalmol. 91(3), 335–339 (2007).
   PubMed Web of Science ®Google Scholar
• Deuter CM, Koetter I, Guenaydin I, Stuebiger N, Zierhut M. Interferon α-2a: a new treatment option for long-lasting refractory cystoid macular edema in uveitis? A pilot study. Retina 26(7), 786–791 (2006).
   PubMed Web of Science ®Google Scholar
• Deuter CM, Kötter I, Günaydin I, Stübiger N, Doycheva DG, Zierhut M. Efficacy and tolerability of interferon α treatment in patients with chronic cystoid macular oedema due to noninfectious uveitis. Br. J. Ophthalmol. 93(7), 906–913 (2009).
   PubMed Web of Science ®Google Scholar
• Sobaci G, Bayraktar Z, Bayer A. Interferon α-2a treatment for serpiginous choroiditis. Ocul. Immunol. Inflamm. 13(1), 59–66 (2005).
   PubMed Web of Science ®Google Scholar
• Becker MD, Heiligenhaus A, Hudde T et al. Interferon as a treatment for uveitis associated with multiple sclerosis. Br. J. Ophthalmol. 89(10), 1254–1257 (2005).
   PubMed Web of Science ®Google Scholar
• Cirino AC, Mathura JR Jr, Jampol LM. Resolution of activity (choroiditis and choroidal neovascularization) of chronic recurrent punctate inner choroidopathy after treatment with interferon B-1A. Retina 26(9), 1091–1092 (2006).
   PubMed Web of Science ®Google Scholar
• Kotter I, Deuter C, Stubiger N, Zierhut M. Interferon-α (IFN-α) application versus tumor necrosis factor-α antagonism for ocular Behçet’s disease: focusing more on IFN. J. Rheumatol. 32(8), 1633; author reply 1634 (2005).
   Google Scholar
• Onal S, Kazokoglu H, Koc A et al. Long-term efficacy and safety of low-dose and dose-escalating interferon α-2a therapy in refractory Behçet uveitis. Arch. Ophthalmol. 129(3), 288–294 (2011).
   PubMed Web of Science ®Google Scholar
• Sobaci G, Erdem U, Durukan AH et al. Safety and effectiveness of interferon α-2a in treatment of patients with Behçet’s uveitis refractory to conventional treatments. Ophthalmology 117(7), 1430–1435 (2010).
   PubMed Web of Science ®Google Scholar
• Muselier A, Bielefeld P, Bidot S, Vinit J, Besancenot JF, Bron A. Efficacy of tocilizumab in two patients with anti-TNF-α refractory uveitis. Ocul. Immunol. Inflamm. 19(5), 382–383 (2011).
   PubMed Web of Science ®Google Scholar
• Zhang R, He R, Qian J, Guo J, Xue K, Yuan YF. Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes. Invest. Ophthalmol. Vis. Sci. 51(7), 3575–3582 (2010).
   PubMed Web of Science ®Google Scholar